宮頸癌是女性常見惡性腫瘤之一。針對(duì)局部晚期及復(fù)發(fā)轉(zhuǎn)移的宮頸癌患者尚未有令人滿意的治療手段，因此探索和發(fā)展更有效的治療方案具有重要的意義。PI3K/AKT/mTOR信號(hào)通路在人類子宮頸癌細(xì)胞的增殖、分化和凋亡中具有重要的調(diào)節(jié)作用，有希望成為開發(fā)宮頸癌治療藥物的新型靶標(biāo)。綜述了近年來PI3K/AKT/mTOR信號(hào)通路的單一及雙重靶點(diǎn)抑制劑針對(duì)宮頸癌的臨床前及臨床研究情況，包括PI3K抑制劑（wortmannin、LY294002、吲哚-3-甲醇）、AKT抑制劑（SC-66、MK-2206、木黃酮、冬凌草甲素和雷公藤）、mTOR抑制劑（替西羅莫司和依維莫司）及雙重靶點(diǎn)抑制劑（GSK2126458、BEZ235、BGT226、PF04691502、GDC-0980和PKI-587）等。

Cervical cancer is a common malignant tumor of women all over the world. There is no satisfactory treatment for cervical cancer patients with locally advanced and recurrent metastases. Therefore, it is of great significance to explore and develop more effective treatment protocols. The PI3K/AKT/mTOR signaling pathway plays an important regulatory role in the proliferation, differentiation, and apoptosis of human cervical cancer cells, and it is hopeful that it will become a new target for the development of therapeutic drugs for cervical cancer. Therefore, preclinical and clinical research on single and dual target inhibitors of cervical cancer on PI3K/AKT/mTOR signaling pathway in this pathway are reviewed in recent years. The inhibitors include PI3K inhibitors (wortmannin, LY294002, and indole-3-methanol), AKT inhibitors (SC-66, MK-2206, flavonoids, oridonide, and tripterygium wilfordii), mTOR inhibitors (CCI-779 and RAD-001), and dual inhibitors (GSK2126458, BEZ235, BGT226, PF04691502, GDC-0980, and PKI-587).

首都醫(yī)科大學(xué)附屬北京婦產(chǎn)醫(yī)院中青年學(xué)科骨干培養(yǎng)專項(xiàng)（fcyy201608）；首都醫(yī)科大學(xué)2017年基礎(chǔ)-臨床科研合作基金資助項(xiàng)目（17JL38）